Targeting NLRP3 with GDC-2394 ameliorates airway inflammation and smooth muscle hyperplasia in experimental asthma by suppressing the IL-6/JAK2/STAT3 axis
Zhiyuan Wang, Zhenzhen Guo, Yanan Wang, Qianqian Dai, Muhammad Imran Arif, Aizetiguli Maiming, Menghua Li, Aliya Maimaitiniyazi, Xueli Wang, Jianjiang Cui, Shengmeng Qu, Wen Zhao, Liang Ru · 2026
Read Targeting NLRP3 with GDC-2394 ameliorates airway inflammation and smooth muscle hyperplasia in experimental asthma by suppressing the IL-6/JAK2/STAT3 axis by Zhiyuan Wang, Zhenzhen Guo, Yanan Wang, Qianqian Dai, Muhammad Imran Arif, Aizetiguli Maiming, Menghua Li, Aliya Maimaitiniyazi, Xueli Wang, Jianjiang Cui, Shengmeng Qu, Wen Zhao, Liang Ru (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13578252.txt.
Description
Zhiyuan Wang and colleagues test a targeted drug in a 2026 mouse study of asthma, a lung disease where swollen airways narrow over time. House dust mite exposure drove the model, which showed thick airway muscle, extra mucus, and high levels of immune signals tied to allergy. The drug blocks NLRP3, a protein hub that switches on inflammation.
Treated mice showed calmer airways, less muscle growth, and fewer mucus cells than untreated ones, while the control fluid alone changed nothing. Muscle growth fell alongside weaker signals on a chain running from the IL-6 signal through two switch proteins. The authors say immune cells may share in the gain, and that more work must test whether blocking this hub can slow airway change in children.
Catalog record
| CREATOR | Zhiyuan Wang, Zhenzhen Guo, Yanan Wang, Qianqian Dai, Muhammad Imran Arif, Aizetiguli Maiming, Menghua Li, Aliya Maimaitiniyazi, Xueli Wang, Jianjiang Cui, Shengmeng Qu, Wen Zhao, Liang Ru |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |